Device-supported myocardial revascularization: safe help for sick hearts

Although advances in both the technology of artificial oxygenation and our understanding of myocardial preservation have made aortocoronary bypass operations safer, clinical settings remain where even these improvements have limited efficacy. We have recently treated 43 severely ill patients with aortocoronary bypass, using a ventricular assist device for intraoperative hemodynamic support and ventricular decompression. For 34 of the patients, preoperative ejection fractions (multigated acquisition) ranged from 0.12 to 0.28 (average, 0.22); 6 patients manifested cardiogenic shock preoperatively, and emergency operations precluded multigated acquisition studies. Twenty-nine patients had preoperative evidence of congestive heart failure, 10 had a prior bypass operation, 9 had major chronic obstructive pulmonary disease, and 2 were Jehovah's Witnesses. The operative technique involved minimal doses of heparin (1 to 1.5 mg/kg), no cardioplegia, and no cardiopulmonary bypass. Revascularization was accomplished on beating, nonworking hearts, with right (40 of 43) and left (43 of 43) ventricles supported by Nimbus Hemopumps (4 of 43) or Bio-Medicus centrifugal ventricular assist devices for an average of 112 minutes. In each case, the patient's lungs were used as the oxygenator. An average of 3.7 bypass grafts per patient were constructed. The left internal mammary artery was used in 41 patients, whereas at least one coronary endarterectomy was required in 20. Six patients had concomitant placement of an automatic implantable cardioverter defibrillator. Two patients (4.6%) died: 1 (with preoperative cardiogenic shock) of low cardiac output on postoperative day 1, and 1 of a severe neurologic deficit on day 8. Follow-up ranged from 2 to 18 months (average, 8.9 months), with all survivors demonstrating improvement in cardiac function in both the early and late postoperative periods.(ABSTRACT TRUNCATED AT 250 WORDS)